Down Syndrome Risk (DSR) – prenatal screening analysis to determine individual risk of Down Syndrome for the first trimester

The risk of Down syndrome (Down syndrome, CRSD) is a concern for expectant parents and doctors during pregnancy. This syndrome is one of the most common chromosomal abnormalities and can affect the development of the child. Prenatal screening, including hormonal panels and biochemical analysis, has become an extremely important tool for determining the individual risk of CRSD during the first trimester of pregnancy.

Before considering prenatal screening, it is important to understand what Down syndrome is. It is a genetic condition that results from having an extra copy of chromosome 21. Down syndrome can lead to a variety of medical problems and psychological challenges in a child, including developmental delays and intellectual disabilities.

Prenatal screening for Down syndrome risk in the first trimester aims to provide parents with more information about the possible risk and to determine whether further diagnostics, such as chorionic villus sampling or amniocentesis, which are usually associated with greater risks to the pregnancy, are necessary.

The main methods of prenatal screening for determining the risk of Down syndrome in the first trimester are a hormonal panel and a biochemical analysis. The hormonal panel involves measuring the levels of two hormones: beta-chorionic gonadotropin (hCG) and progesterone in the mother's blood. This data, together with the mother's age, weight, and other factors, is used to calculate the risk of Down syndrome.

Biochemical testing involves measuring the levels of two proteins in the mother's blood: alpha-fetoprotein (AFP) and free estriol (uE3). These proteins, along with a hormone panel, can more accurately determine the risk of CRSD.

Fortunately, many low-risk pregnancies do not result in a baby with Down syndrome. Prenatal screening in the first trimester provides an opportunity to identify high risk and begin discussing possible next steps with your doctor in good time. In most cases where high risk is suspected, further testing, such as amniocentesis, is recommended to accurately determine the presence of Down syndrome in the fetus.

It is important to remember that screening results are not a definitive diagnosis, and many factors can affect the accuracy of these tests. A high risk does not mean that the baby will definitely have Down syndrome, and a low risk does not guarantee that the baby will not have the syndrome. Therefore, it is important to discuss the results with your doctor and make an informed decision about further diagnosis and pregnancy management.

In summary, prenatal screening in the first trimester, including hormonal panel and biochemical analysis, are important tools for determining individual risk for Down syndrome. These tests allow parents and doctors to obtain more information and initiate the necessary diagnosis and treatment in a timely manner in cases of high risk.